How many drugs treat Cholangitis?

Drug Landscape tracks 10 marketed treatments for Cholangitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/cholangitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cholangitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cholangitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cholangitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Unasyn	SULBACTAM	Pfizer	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Kanacin	KANAMYCIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial	Gap junction beta-2 protein	1973-01-01
Ancef In Sodium Chloride 0.9% In Plastic Container	CEFAZOLIN	GSK	Cephalosporin Antibacterial		1973-01-01
Ancef In Sodium Chloride 0.9% In Plastic Container	Cefazolin Sodium	GSK	Cephalosporin	Bacterial cell wall peptidoglycan	1973-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Eryped	Erythromycin ethyl succinate	Arbor Pharms Llc	Macrolide		1965-01-01
Cefazoline	Cefazoline	Nantes University Hospital		Bacterial penicillin-binding protein, Penicillin-binding protein 1A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cholangitis:

Cite this brief

Drug Landscape (2026). Cholangitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cholangitis. Accessed 2026-06-10.

Cholangitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing